These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21755502

  • 41. Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
    Ferrer E, del Rio L, Martínez E, Curto J, Domingo P, Ribera E, Negredo E, Rosales J, Saumoy M, Ordóñez J, Gatell JM, Podzamczer D.
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1061-5. PubMed ID: 21166602
    [Abstract] [Full Text] [Related]

  • 42. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H, Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [Abstract] [Full Text] [Related]

  • 43. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH, Nassar N.
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [Abstract] [Full Text] [Related]

  • 44. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P, Prieto L, Jiménez De Ory S, Fernández Cooke E, Navarro ML, Ramos JT, Holguín Á, Madrid Cohort of HIV-1 Infected Children and Adolescents Integrated in the Paediatric Branch of the Spanish National AIDS Network (CoRISPe).
    PLoS One; 2017 Aug; 12(3):e0173168. PubMed ID: 28350802
    [Abstract] [Full Text] [Related]

  • 45. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J, Litau E, Sing T, Däumer M, Balduin M, Oette M, Fätkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R.
    Antivir Ther; 2006 Aug; 11(7):879-87. PubMed ID: 17302250
    [Abstract] [Full Text] [Related]

  • 46. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
    Santoro MM, Svicher V, Gori C, Zaccarelli M, Tozzi V, Forbici F, D'Arrigo R, Trotta MP, Bellocchi MC, Visco-Comandini U, Cenci A, Bertoli A, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F.
    New Microbiol; 2006 Apr; 29(2):89-100. PubMed ID: 16841549
    [Abstract] [Full Text] [Related]

  • 47. [Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital].
    Fernández Lisón LC, Fernández Pereira LM, Romero Chala S.
    Farm Hosp; 2011 Apr; 35(4):191-6. PubMed ID: 21087876
    [Abstract] [Full Text] [Related]

  • 48. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.
    Antivir Ther; 2007 Apr; 12(8):1237-46. PubMed ID: 18240863
    [Abstract] [Full Text] [Related]

  • 49. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF, MONARK Study Group.
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L, Manfredi R, Pocaterra D, Chiodo F.
    Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
    [Abstract] [Full Text] [Related]

  • 51. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients.
    Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, Bernstein BM, Japour AJ, Sun E, Rode RA.
    J Virol; 2001 Aug; 75(16):7462-9. PubMed ID: 11462018
    [Abstract] [Full Text] [Related]

  • 52. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ, Hullsiek KH, Leduc R, Novak RM, MacArthur RD, Lawrence J, Baxter JD, Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).
    Antivir Ther; 2006 Aug; 11(4):457-63. PubMed ID: 16856619
    [Abstract] [Full Text] [Related]

  • 53. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 54. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 27; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 55. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
    Smith CJ, Phillips AN, Youle MS, Sabin CA, Lampe FC, Tsintas R, Tyrer M, Johnson MA.
    HIV Med; 2007 Jan 27; 8(1):55-63. PubMed ID: 17305933
    [Abstract] [Full Text] [Related]

  • 56. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients.
    Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D, ANRS CO5 HIV-2 Cohort.
    AIDS; 2013 Jan 02; 27(1):69-80. PubMed ID: 23018441
    [Abstract] [Full Text] [Related]

  • 57. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
    Gilliam BL, Chan-Tack KM, Qaqish RB, Rode RA, Fantry LE, Redfield RR.
    AIDS Patient Care STDS; 2006 Nov 02; 20(11):745-59. PubMed ID: 17134349
    [Abstract] [Full Text] [Related]

  • 58. Ongoing HIV replication in cerebrospinal fluid under successful monotherapy.
    Bierhoff M, Boucher CA, Fibriani A, Ten Kate RW.
    Antivir Ther; 2013 Nov 02; 18(4):641-3. PubMed ID: 23344463
    [Abstract] [Full Text] [Related]

  • 59. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
    Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.
    J Antimicrob Chemother; 2012 Apr 02; 67(4):995-1000. PubMed ID: 22258921
    [Abstract] [Full Text] [Related]

  • 60. Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.
    Giandhari J, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, Kuhn L, Hunt G, Morris L.
    Antimicrob Agents Chemother; 2016 Apr 02; 60(4):2248-56. PubMed ID: 26833162
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.